Gemcitabine is then phosphorylated into gemcitabine monophosphate (dFdCMP) by deoxycytidine kinase (DCK), and dFdCMP is subsequently phosphorylated to gemcitabine diphosphate (dFdCDP) and ...

Gemcitabine is a prodrug that is initially phosphorylated by deoxycytidine kinase (dCK) to gemcitabine monophosphate and subsequently to gemcitabine diphosphate and gemcitabine triphosphate.

Subsequently, dFdCMP is phosphorylated to gemcitabine diphosphate (dFdCDP) by CMPK1, and then dFdCDP is converted to gemcitabine triphosphate (dFdCTP; major active metabolite) by nucleotide kinases.

Background: Motesanib diphosphate is an oral investigational, highly selective inhibitor of VEGF, PDGF and Kit receptors. In advanced cancer, inhibition of EGFR and VEGFR, with or without chemotherapy ...

Gemcitabine chemotherapy is used for advanced cancers of the breast, lungs, ovaries, and pancreas. Learn about delivery, side effects, effectiveness, and more.

Gemcitabine has been used since 1997 as a treatment for advanced unresectable pancreatic cancer, and it is a potent radiosensitizer. Dr. Loehrer and colleagues examined the role, among patients ...

Yes. The randomized phase 3 APACT trial was a well-designed adjuvant trial that evaluated the addition of nab-paclitaxel (Abraxane, Celgene) to gemcitabine — the combination was planned based ...

PATIENTS AND METHODS: Patients with unresectable LMS of uterine (n = 29) or other (n = 5) primary sites who did not respond to zero to two prior chemotherapy regimens were enrolled onto a phase II ...

After a median follow-up of 8.2 months and 327 deaths, the median overall survival was 11.7 months among the 204 patients in the cisplatin–gemcitabine group and 8.1 months among the 206 patients ...

Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to ...

London, UK, 9 March 2009 - The oncology product Gemcitabine, produced by Actavis Group, the international generic pharmaceuticals company, was launched in EU markets, at patent expiry. The launch ...

Gemcitabine at a dose of 1 g per square meter of body-surface area on days 1 and 8 and cisplatin at a dose of 80 mg per square meter on day 1 were administered intravenously once every 3 weeks for ...